Alexander E, Goldberg L, Das AF, et al. - Through a randomized clinical trial done at 99 sites in 19 countries, involving 738 individuals, researchers assessed the efficiency and adverse events of a 5-day oral lefamulin regimen in individuals with community-acquired bacterial pneumonia (CABP). With both lefamulin and moxifloxacin, early clinical response rates was 90.8%. In the modified intent-to-treat population, rates of analyst evaluation of clinical response success were 87.5% with lefamulin vs 89.1% with moxifloxacin and 89.7% and 93.6%, respectively, in the clinically assessable population at the test of cure. The most commonly announced treatment-emergent adverse events were gastrointestinal. Thus, following the first dose, 5-day oral lefamulin was noninferior to 7-day oral moxifloxacin among patients with CABP, relative to early clinical response at 96 hours.